https://www.pharmanow.live/latest-news/neilmed-pharmaceuticals-fda-warning-letter-glycerin-identity-testing-2023 2026-10-28T11:12:09+05:30 Pharma Now en 2026-10-27T00:00:00+05:30 FDA Flags NeilMed Glycerin Testing Failures in Warning Letter FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-neilmed-pharmaceuticals-warning-letter-glycerin-identity-testing-202320261028111126.webp https://www.pharmanow.live/latest-news/neilmed-pharmaceuticals-fda-warning-letter-closeout-2026 2026-10-27T22:37:54+05:30 Pharma Now en 2026-10-27T00:00:00+05:30 NeilMed Pharmaceuticals Secures FDA Warning Letter Closeout After Three-Year CAPA Recovery NeilMed https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/0795ad9d-77bc-41db-a6ce-70cad0128da0/be43236d-8b52-4016-bc68-60a68fca95d5.png https://www.pharmanow.live/latest-news/fda-draft-guidance-bla-individualized-genome-editing-products-2026 2026-10-27T22:39:03+05:30 Pharma Now en 2026-10-27T00:00:00+05:30 FDA Issues Draft Guidance on BLA Submissions for Individualized Genome Editing Products FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/0795ad9d-77bc-41db-a6ce-70cad0128da0/88ad0c50-3080-4ce5-b122-df25f1226b06.png https://www.pharmanow.live/latest-news/beaute-bounty-fda-cber-warning-letter-unlicensed-stem-cell-placenta-biologics 2026-10-27T22:41:21+05:30 Pharma Now en 2026-10-27T00:00:00+05:30 Beaute Bounty Receives FDA CBER Warning Letter for Unlicensed Stem Cell and Placenta Biologics FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/0795ad9d-77bc-41db-a6ce-70cad0128da0/924a3082-0ed0-41f6-af47-65c2aa5ee72c.png https://www.pharmanow.live/latest-news/fda-warning-letter-best-chinese-medicines-llc-unapproved-drugs-2026 2026-10-27T22:45:15+05:30 Pharma Now en 2026-10-27T00:00:00+05:30 FDA Issues Warning Letter to Best Chinese Medicines LLC Over Five Unapproved Drug Products FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/0795ad9d-77bc-41db-a6ce-70cad0128da0/3a616602-66b1-4111-8cd4-df4d871774e3.png https://www.pharmanow.live/latest-news/alembic-pharmaceuticals-usfda-final-approval-valganciclovir-oral-solution-cmv-retinitis 2026-10-28T11:58:47+05:30 Pharma Now en 2026-10-27T00:00:00+05:30 Alembic Wins USFDA Approval for Valganciclovir Oral Solution Alembic https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/alembic-usfda-valganciclovir-oral-solution-approval-cmv-retinitis-202620261028115749.webp https://www.pharmanow.live/latest-news/abbvie-submits-bla-etentamig-fda-relapsed-refractory-multiple-myeloma 2026-10-28T11:53:06+05:30 Pharma Now en 2026-10-27T00:00:00+05:30 AbbVie Submits FDA Application for Etentamig in Multiple Myeloma AbbVie https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/abbvie-etentamig-bla-fda-relapsed-refractory-multiple-myeloma-202620261028115212.webp https://www.pharmanow.live/latest-news/worlds-biggest-microbiology-ccs-summit-pharmig-india-2026-unites-global-microbiology-ccs-leaders-in-hyderabad 2026-10-27T19:48:53+05:30 Pharma Now en 2026-10-27T19:48:39+05:30 World's Biggest Microbiology & CCS Summit ‘Pharmig India 2026’ Unites Global Microbiology & CCS Leaders in Hyderabad Pharmig India 2026, microbiology summit India, contamination control strategy summit, pharmaceutical microbiology conference, Pharmig Hyderabad 2026 https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/pharmig_india_2026_hyderabad_website_press_release20261027194806.png https://www.pharmanow.live/latest-news/bristol-myers-squibb-phase-3-egfrxher3-bispecific-adc-lung-cancer 2026-10-28T11:44:44+05:30 Pharma Now en 2026-10-27T00:00:00+05:30 BMS-Partnered Iza-Bren Doubles PFS in Phase 3 Lung Cancer Trial BMS https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/bms-izalontamab-brengitecan-iza-bren-phase-3-lung-cancer-pfs-202620261028114336.webp https://www.pharmanow.live/latest-news/roche-divarasib-phase-iii-kras-lung-cancer-mortality-reduction 2026-10-28T11:26:53+05:30 Pharma Now en 2026-10-27T00:00:00+05:30 Roche Divarasib Cuts Death Risk by 44% in Phase 3 Lung Cancer Roche https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/roche-divarasib-phase-3-kras-lung-cancer-mortality-reduction-202620261028112518.webp https://www.pharmanow.live/latest-news/merck-pimicotinib-sustained-response-pvns-phase-3-trial 2026-10-28T11:16:50+05:30 Pharma Now en 2026-10-27T00:00:00+05:30 Merck Reports Durable Two-Year Responses in Phase 3 TGCT Trial Merck https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/merck-pimicotinib-phase-3-maneuver-tgct-durable-tumor-response-202620261028111557.webp https://www.pharmanow.live/latest-news/darolutamide-phase-iii-58-percent-metastasis-risk-reduction-high-risk-prostate-cancer 2026-10-27T22:27:39+05:30 Pharma Now en 2026-10-27T00:00:00+05:30 Darolutamide Achieves 58% Metastasis Risk Reduction in Phase III High-Risk Prostate Cancer Trial Darolutamide https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/b52b9af1-20b8-4883-b73c-e1620361a8e6/4e1e2c88-96f1-4080-8d40-0363b1fca911.png https://www.pharmanow.live/latest-news/roche-sefaxersen-phase-iii-proteinuria-reduction-iga-nephropathy 2026-10-28T11:05:28+05:30 Pharma Now en 2026-10-27T00:00:00+05:30 Roche Reports 43.1% Proteinuria Reduction in Phase 3 IgAN Trial Roche https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/roche-sefaxersen-phase-3-proteinuria-reduction-igan-202620261028105934.webp https://www.pharmanow.live/latest-news/lilly-olomorasib-kras-lung-cancer-durable-responses-early-trial 2026-10-28T10:51:43+05:30 Pharma Now en 2026-10-27T00:00:00+05:30 Lilly Reports Durable Olomorasib Responses in KRAS Lung Cancer Lilly https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/lilly-olomorasib-kras-g12c-lung-cancer-durable-responses-esmo-202620261028105044.webp https://www.pharmanow.live/latest-news/biontech-bms-pumitamig-lung-cancer-367-response-rate 2026-10-28T10:43:22+05:30 Pharma Now en 2026-10-27T00:00:00+05:30 BioNTech Reports 36.7% Response Rate for Pumitamig in Lung Cancer BioNTech https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/biontech-bms-pumitamig-36-7-response-rate-lung-cancer-202620261028104106.webp https://www.pharmanow.live/latest-news/zyduss-moraiya-plant-closes-fda-inspection-with-5-observations 2026-10-27T07:47:24+05:30 Pharma Now en 2026-10-16T00:00:00+05:30 Zydus's Moraiya plant closes FDA inspection with 5 observations FDA Inspection, Zydus Lifesciences, Warning Letter, 483 Form https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/moraiyafact-01-jpg20261027071220.jpg https://www.pharmanow.live/latest-news/pfizer-fda-approval-talazoparib-enzalutamide-hrr-mutated-mapms-prostate-cancer 2026-10-27T07:46:01+05:30 Pharma Now en 2026-10-27T00:00:00+05:30 Pfizer Gains FDA Approval for Talazoparib Plus Enzalutamide in HRR-Mutated mAPMN/S Prostate Cancer talazoparib, Prostate Cancer, Pfizer https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/Pfizer_HQ_Entrance_1600X900_opt20261027074057.jpg https://www.pharmanow.live/latest-news/hepion-pharmaceuticals-fda-feedback-gv104-fentanyl-prophylaxis-nda 2026-10-27T10:49:22+05:30 Pharma Now en 2026-10-26T00:00:00+05:30 Hepion Pharmaceuticals Gains FDA Backing for GV104 Modeling Hepion https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/hepion-gv104-fda-feedback-fentanyl-prophylaxis-modeling-202620261027104648.webp https://www.pharmanow.live/latest-news/fda-extends-coral-snake-antivenin-lot-cl6814-expiration-june-2026 2026-10-27T10:44:56+05:30 Pharma Now en 2026-10-26T00:00:00+05:30 FDA Extends Coral Snake Antivenin Lot CL6814 to December 2026 FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-coral-snake-antivenin-lot-cl6814-expiration-extension-december-202620261027104003.webp https://www.pharmanow.live/latest-news/orchid-pharma-signs-80m-latin-america-deal-exblifep-nine-markets 2026-10-27T10:29:57+05:30 Pharma Now en 2026-10-26T00:00:00+05:30 Orchid Pharma Signs $80M Exblifep Deal Across Nine Markets Orchid https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/orchid-pharma-exblifep-80m-latin-america-deal-nine-markets-202620261027102735.webp https://www.pharmanow.live/latest-news/pfizer-25-valent-pneumococcal-vaccine-phase-2-results-infants 2026-10-27T10:20:45+05:30 Pharma Now en 2026-10-26T00:00:00+05:30 Pfizer Reports Positive Phase 2 Data for 25-Valent Infant Vaccine Pfizer https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/pfizer-25-valent-pneumococcal-vaccine-phase-2-infant-results-202620261027101902.webp https://www.pharmanow.live/latest-news/artelo-biosciences-art26-12-fabp5-inhibitor-mad-study-phase-1 2026-10-27T10:10:44+05:30 Pharma Now en 2026-10-26T00:00:00+05:30 Artelo Biosciences Advances ART26.12 Into MAD Study Artelo https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/artelo-art26-12-fabp5-inhibitor-phase-1-mad-study-q4-202620261027101028.webp https://www.pharmanow.live/latest-news/v-shapes-single-dose-packaging 2026-10-26T15:25:08+05:30 Pharma Now en 2026-10-26T00:00:00+05:30 V-Shapes Single-Dose Packaging for Nutraceuticals, Skincare V-Shapes single-dose packaging https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/v-shapes-single-dose-packaging20261026152219.webp